FGFR2 and adenocarcinoma: The proportion of FGFR2-amplified adenocarcinomas was higher in treatment-naïve patients (13/144, 7.3%) than in neoadjuvant-treated patients (8/252, 3.2%), resulting in an approximate 1/3 to 2/3 distribution of naïve to neoadjuvant-treated tumors within FGFR2-amplified esophageal adenocarcinomas.